Tumor organoids for testing metabolic flexibility in precision oncology

Tumors adapt their metabolism to fluctuating nutrients, hypoxia, stromal interactions, immune pressure, and treatment. Tumor organoids are attractive systems in which to test this flexibility, but existing reviews have largely emphasized organoid applications, physiologic culture conditions or metabolomics workflows rather than the strength of evidence behind individual metabolic claims. Here, we address a narrower problem: which metabolic properties of a patient tumor are directly retained or recreated in organoid culture? We evaluate organoid evidence using three levels of support: direct metabolic measurements and perturbation in organoids, biological mechanisms established in other models that require organoid validation, and translational associations that require prospective clinical testing. Recent studies provide direct advances in pancreatic cancer organoids, including subtype-specific oxidative and glycolytic states, KRAS-associated cholesterol dependence and hypoxia-driven invasion, and in gastric and colorectal models where engineered co-cultures expose niche-dependent lipid or immune responses. These findings also expose a central gap: matched benchmarking of organoid metabolic flux and spatial heterogeneity against native tumors remains uncommon. We propose a validation framework based on physiologically specified environments, spatial and isotope-resolved measurements, multi-compartment co-culture and prospective linkage of functional readouts to patient outcomes. Tumor organoids can therefore advance cancer metabolism most credibly as tested, context-specific models rather than assumed replicas of metabolic flexibility in vivo.